Leverage • Atrium Therapeutics
RNA
Atrium Therapeutics Inc. is a clinical-stage biopharmaceutical company pioneering the development of atrial-selective gene therapies for the treatment of atrial fibrillation (AFib), the most prevalent sustained cardiac arrhythmia worldwide. The company's mission is to provide a durable, one-time treatment that restores and maintains normal sinus rhythm, addressing the limitations of current standard-of-care treatments such as anti-arrhythmic drugs and catheter ablation. Atrium's proprietary platform focuses on localized delivery of genetic material to the heart's atria. Its lead product candidate, ATR-101, is an investigational gene therapy designed to be delivered via a single administration to the epicardial surface of the atria during a minimally invasive procedure or concomitant with cardiac surgery. ATR-101 works by expressing a modified potassium channel that prolongs the atrial refractory period, thereby suppressing the electrical triggers and substrates that sustain AFib. By targeting the underlying electrophysiological mechanisms of the disease specifically within the atrial tissue, Atrium Therapeutics aims to minimize systemic side effects and improve long-term outcomes for patients suffering from paroxysmal or persistent AFib. The company is positioned at the intersection of cardiovascular medicine and advanced genetic therapeutics, seeking to fill a significant unmet need in the management of chronic heart rhythm disorders.
2,2
N.D./EBITDA
How many years of EBITDA are required to pay off the company's net debt, according to the official accounting standard IFRS16. As a market consensus, a value of up to 3 years of leverage is accepted for most companies.
0%
Debt/Equity
How much the company's debt represents in % in relation to its equity. As a market consensus, a value less than or equal to 1 is accepted, above that leverage can end up hurting the final result at some point.
0,1
Current Ratio
The current ratio helps investors understand more about a company's ability to cover its short-term debt with its current assets and make apples-to-apples comparisons with its competitors and peers.
0
Quick Ratio
The quick ratio measures a company's capacity to pay its current liabilities without needing to sell its inventory or obtain additional financing and is considered a more conservative measure than the current ratio, which includes all current assets as coverage for current liabilities.
—
Interest Coverage
The interest coverage ratio is used to measure how well a firm can pay the interest due on outstanding debt and is is calculated by dividing a company's earnings before interest and taxes (EBIT) by its interest expense during a given period. Generally, a higher coverage ratio is better, although the ideal ratio may vary by industry.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!